TABLE 1.

Patient characteristics

Characteristics	LMF + bevacizumab + temozolomide	Bevacizumab Cohort	TCGA Cohort	Vanderbilt/UCSF Cohort
n (pathology)	14 (13 GBM, 1 AA)	50 (all GBM)	10 (all GBM)	5 (all GBM)
Age, median (range), years	59 (41–71)	58 (18–75)	60 (36–72)	56 (38–72)
Gender (%)
Male	86	52	67	25
Female	14	48	33	75
KPS, median (range)	80 (60–90)	80 (50–100)	d	80 (70–90)
Received chemoradiation with temozolomide (%)	100	100	100	100
MGMT methylated (%)a	33	b	b	b
IDH mutated (%)	0	b	0	0
Median exposure to LMF (range), daysc	192 (46–701)	–	–	–

^aNine of the 14 samples had MGMT methylation data and all were IDH wild-type.

^bIn the majority of these patients the MGMT and IDH status were not known.

^cDays to progression.

^dKPS is not known for TCGA samples.

Abbreviation: KPS = Karnosfsky performance status.